EUVIMEDEUVIMED entdecken
Fallbericht

Dual Antibody Treatment for Simultaneous Acute Cellular Rejection and Antibody-Mediated Rejection After Liver Transplantation: A Case Report

Kenei Furukawa, Koichiro Haruki, Mureo Kasahara, Tomohiko Taniai, Toru Ikegami

Transplantation Proceedings · 2023

DOI: 10.1016/j.transproceed.2023.03.093 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Transplantation Proceedings, 2023. Verfasst von Kenei Furukawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo Japan. Electronic address: k-fu…. Hauptthemen laut MEDLINE: Liver Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Jikei University School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-mediated rejection (AMR) after liver transplantation is uncommon but sometimes has a grave prognosis. We herein describe a 40-year-old man who developed simultaneous acute cellular rejection and acute AMR due to de novo donor-specific anti-human leukocyte antigen antibodies after living donor liver transplantation. He underwent living donor liver transplantation with his brother-in-law as the donor. Hepatic function deteriorated on postoperative day 6, and a liver biopsy revealed histologic findings of typical acute cellular rejection. However, steroid pulse therapy and thymoglobulin did not produce a clinical response, and his liver function dramatically deteriorated on postoperative day 13 (aspartate aminotransferase, 2787 IU/L; total bilirubin, 14.1 mg/dL). We diagnosed acute AMR based on positive immunohistochemical staining for C4d in portal areas and added plasma exchange and high-dose intravenous immunoglobulin after rituximab. The patient's clinical state improved and ultimately resolved. To our knowledge, this is the first report of dual antibody treatment for simultaneous acute cellular rejection and acute AMR induced by de novo donor-specific anti-human leukocyte antigen antibodies. Despite his fulminant clinical course, we successfully rescued the recipient with immediate anti-humoral therapy. The rapid treatment decision and adequate understanding of the mechanisms of anti-humoral therapy were crucial to overcoming acute AMR in this case.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationMaleHumansAdultLiving DonorsTreatment OutcomeAntibodiesRituximabHLA AntigensGraft RejectionIsoantibodies

Substanzen

AntibodiesRituximabHLA AntigensIsoantibodies

Autor:innen und Institutionen

  • Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo Japan. Electronic address: k-furukawa@jikei.ac.jp.
  • Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo Japan.
  • Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

Förderung

  • Jikei University School of Medicine

Zitieren

APA

Furukawa, K., Haruki, K., Kasahara, M., Taniai, T., & Ikegami, T. (2023). Dual Antibody Treatment for Simultaneous Acute Cellular Rejection and Antibody-Mediated Rejection After Liver Transplantation: A Case Report. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2023.03.093

Vancouver

Furukawa K, Haruki K, Kasahara M, Taniai T, Ikegami T. Dual Antibody Treatment for Simultaneous Acute Cellular Rejection and Antibody-Mediated Rejection After Liver Transplantation: A Case Report. Transplantation Proceedings. 2023. doi:10.1016/j.transproceed.2023.03.093

BibTeX
@article{Furukawa2023,
  author = {Furukawa, Kenei and Haruki, Koichiro and Kasahara, Mureo and Taniai, Tomohiko and Ikegami, Toru},
  title = {Dual Antibody Treatment for Simultaneous Acute Cellular Rejection and Antibody-Mediated Rejection After Liver Transplantation: A Case Report},
  journal = {Transplantation Proceedings},
  year = {2023},
  doi = {10.1016/j.transproceed.2023.03.093}
}
Kostenlos starten →